Cholestech (CTEC) Partners with Onsite Health Diagnostics for On-site, Corporate Health Screenings
More News related to CTEC
- China Agritech Receives Approval for NASDAQ Listing; New Symbol "CAGC"
- China Agritech, Inc. Approved for Listing on the NASDAQ Global Market
- China Agritech, Inc. Completes Construction of Xinjiang Organic Granular Fertilizer Factory
- Cholestech (CTEC) Receives FDA CLIA Waived Status for New Combined Test Panel
- Stifel Nicolaus Upgrades Inverness Medical Innovations (IMA) to Buy
More News related to Corporate News
- Ardour Upgrades Exide Tech. (XIDE) to Buy, $9 Target
- Citi Upgrades Mirant (MIR) to Hold
- Howard Weil Upgrades St. Mary Land & Exploration (SM) to Market Outperform
- Citi Upgrades Shanda Interactive Entertainment (SNDA) to Hold
- Hasbro (HAS) Higher as Stifel Nicolaus Upgrades, Adds to 'Select List'
Cholestech Corporation (Nasdaq: CTEC) has teamed up with Onsite Health Diagnostics, one of the largest providers of comprehensive, on-site, corporate health screenings. The agreement, valued at an estimated $3 million dollars over the next three years, establishes Cholestech LDX testing system as the preferred device for Onsite screeners to monitor for risk factors associated with stroke, heart disease, diabetes and inflammatory disorders.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
